Sai Life Sciences closes trading window from Oct 1 for Q2FY27 results
- Trading window closed from October 1, 2026, for Q2FY27 results
- Restriction applies to designated persons and immediate relatives
- Window reopens 48 hours after financial results announcement
- Board meeting date to be announced later

*this image is generated using AI for illustrative purposes only.
Sai Life Sciences Limited has closed its trading window effective October 1, 2026, in preparation for the declaration of unaudited financial results for the second quarter and half year ending September 30, 2026.
The closure applies to all designated persons and their immediate relatives as per the company's code of conduct. This measure ensures compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, preventing any dealing in the company's securities during the sensitive period.
Trading restrictions and timeline
The trading window remains closed until the end of 48 hours after the announcement of the Q2FY27 results. During this period, insiders are prohibited from entering any transaction involving the buying or selling of Sai Life Sciences shares.
| Event | Date / Timeline |
|---|---|
| Trading window closure start | October 1, 2026 |
| Financial period covered | Q2FY27 and H1FY27 (ending Sep 30, 2026) |
| Trading window reopening | 48 hours after results announcement |
| Board meeting date | To be intimated in due course |
Regulatory compliance
The company filed this notice with both the National Stock Exchange of India Limited and BSE Limited on September 28, 2026. The filing was signed by Runa Karan, Company Secretary and Compliance Officer. The specific date for the board meeting to consider and approve the financial results has not yet been disclosed and will be communicated separately.
Historical Stock Returns for Sai Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.38% | -0.90% | +8.97% | +56.68% | +79.92% | +107.43% |
How will Sai Life Sciences' Q2FY27 revenue growth compare to the previous quarter given the current global CDMO demand environment?
What impact might the upcoming financial results have on the company's stock volatility once the trading window reopens?
Are there any anticipated changes in capital expenditure guidance for FY27 that could influence investor sentiment post-results?






























